Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Dual combination therapy with metformin and sulphonylurea is the most commonly used
combination regimen to treat patients with type 2 diabetes. But, treatment with the dual
combination therapy is often unsuccessful at achieving glycaemic control in patients with
type 2 diabetes. In this setting, use of insulin is often the next therapeutic step.
Recently, dipeptidyl peptidase (DPP)-IV inhibitor is increasingly being used in clinical
practice. It is well established that DPP-IV inhibitor improve glycemic control in patients
with type 2 diabetes.
But, there have been few studies about the glucose lowering effect of DPP-IV inhibitors
(vildagliptin) in Type 2 diabetes patients on the dual combination therapy with a
sulfonylurea agent and metformin.The researchers hypothesized that DPP-IV inhibitor as add-on
therapy to combination of a sulfonylurea agent and metformin have favorable glucose lowering
effect in type 2 diabetic patients. The researchers plan to investigate the change in HbA1C
and fasting glucose of 24 weeks treatment with vildagliptin (DPP-IV inhibitor) in combination
with a sulfonylurea agent and metformin in type 2 diabetic patients.